Vivani Medical, Inc., has announced full enrolment and successful initial dosing of all participants in its phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to 12-months of continuous drug delivery utilising its proprietary NanoPortal technology.
The trial of 20 GLP-1 naive participants in Australia includes low-doses of NPM-139 and Wegovy to assess safety, tolerability and pharmacokinetics. Changes in weight will be measured.
This milestone follows NPM-139 preclinical studies demonstrating sustainable 20% weight reduction in animal models and a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and Vivani’s proprietary NanoPortal implant technology.
In addition to NPM-139’s primary aim to improve convenience, medication adherence and tolerability, NanoPortal implants are uniquely designed to enable infrequent administration (six months or longer) and the ability to rapidly reverse GLP-1 drug exposure when cessation of therapy is needed or desired. Reversibility can be an important clinical consideration in certain situations, including when a woman becomes pregnant or when patients undergoing surgery have an increased aspiration risk.
